top of page
NemaLife YouTube Banner-2.png

NemaLife News

  • Press

Canopy Growth presents toxicity data of cannabigerol in C. elegans

Canopy Growth Corporation's Vice President of Human & Animal Research,

Dr. Marcel Bonn-Miller is giving a talk about the long-term effects of cannabigerol (CBG) in mice and nematodes at the CannX Medical Cannabis Conference.

Similar to CBD, CBG is a phytocannabinoid, with an increasing presence in the worldwide ‘cannabis’ marketplace. Despite the growing pre-clinical literature, no formal toxicity studies had been carried out using CBG

before this study, which includes data from NemaLife's in vivo toxicity platform.

Marcel Bonn-Miller Canopy Growth Corporation, Canada

Dr. Bonn-Miller earned a BA in psychology and PhD in clinical psychology from the University of Vermont. He completed a pre- doctoral clinical psychology internship at the Veterans Affairs Palo Alto Health Care System and a joint postdoctoral fellowship at the Veterans Affairs Palo Alto Health Care System & Stanford University School of Medicine. Dr. Bonn-Miller began his career at the Department of Veterans Affairs, where he held national positions at the Center of Excellence for Substance Abuse Treatment and Education and National Center for PTSD. After almost a decade within the VA, Dr. Bonn-Miller left to take a position at Zynerba Pharmaceuticals where he served as Director of Cannabinoid Research. After 3 years of work with Zynerba Pharmaceuticals, Dr. Bonn-Miller joined Canopy Growth Corporation where he currently serves as Vice President, Human and Animal Research. Widely considered one of the early and leading research pioneers in the field of cannabis and mental health, Dr. Bonn-Miller has conducted seminal work on the interrelations between cannabis and a range of health conditions, including pain, anxiety, HIV, PTSD, and sleep disorders. Dr. Bonn-Miller brings a unique and diverse perspective to cannabinoid therapeutics, having worked within medical center and academic settings for over a decade and with industry for the past 6 years. He serves on the editorial boards of several scientific journals, has published over 150 peer-reviewed empirical publications on cannabis, and has received dozens of Federal and State grants to support his research.


bottom of page